4//SEC Filing
Auspex Pharmaceuticals, Inc. 4
Accession 0001193805-15-000681
CIK 0001454189operating
Filed
May 6, 8:00 PM ET
Accepted
May 7, 1:38 PM ET
Size
49.0 KB
Accession
0001193805-15-000681
Insider Transaction Report
Form 4
Flynn James E
10% OwnerOther
Transactions
- Disposition from Tender
Common Stock
2015-05-05−490,069→ 0 total(indirect: Through Deerfield Special Situations Fund, L.P.) - Disposition from Tender
Common Stock
2015-05-05−953,286→ 0 total(indirect: Through Deerfield Partners, L.P.) - Disposition from Tender
Common Stock
2015-05-05−1,182,943→ 0 total(indirect: Through Deerfield International Master Fund, L.P.) - Disposition from Tender
Common Stock
2015-05-05−849,426→ 0 total(indirect: Through Deerfield Private Design Fund II, L.P.) - Disposition from Tender
Common Stock
2015-05-05−973,379→ 0 total(indirect: Through Deerfield Private Design International II, L.P.)
Footnotes (3)
- [F1]On May 5, 2015, the Issuer announced the closing of its merger with Aurum Merger Sub, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries, Ltd. ("Teva"). At the effective time of the merger, each outstanding share of Common Stock was converted automatically into the right to receive $101, and the Issuer became a wholly-owned subsidiary of Teva.
- [F2]This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- [F3]In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Documents
Issuer
Auspex Pharmaceuticals, Inc.
CIK 0001454189
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001454189
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 1:38 PM ET
- Size
- 49.0 KB